MedTrace Logo

Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol

NCT02871362 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-03-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-118 on the systolic and diastolic blood pressure (BP) and to explore the effects on parameters of lipid metabolism in subjects with elevated BP and low density lipoprotein cholesterol (LDL-C) levels in a pilot study.

Conditions

  • Blood Pressure
  • Low Density Lipoprotein Cholesterol Level

Interventions

DIETARY_SUPPLEMENT

IQP-AS-118

Take one a day

DIETARY_SUPPLEMENT

Placebo

Take one a day

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack, MD, phD · analyze & realize GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2018-01-30
Completion
2018-01-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02871362 on ClinicalTrials.gov